olmutinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| tyrosine kinase inhibitors | 5210 | 1353550-13-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Olmutinib is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) for the treatment of non-small cell lung cancer (NSCLC). Third-generation EGFR TKIs with covalent binding to the receptors demonstrate irreversible enzymatic inhibition of activating EGFR mutations and T790M mutation (a common reason for acquired EGFR TKI resistance), while sparing wild-type EGFR.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | Korean Food and Drug Administration (KFDA) |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01EB06 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Non-small cell lung cancer | indication | 254637007 | DOID:3908 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.82 | acidic |
| pKa2 | 8.43 | Basic |
| pKa3 | 5.75 | Basic |
| pKa4 | 1.26 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Epidermal growth factor receptor | Kinase | INHIBITOR | IC50 | 8.04 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Tyrosine-protein kinase BTK | Kinase | IC50 | 9 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| CHL9B67L95 | UNII |
| 1842366-97-5 | SECONDARY_CAS_RN |
| C4301624 | UMLSCUI |
| CHEMBL3786343 | ChEMBL_ID |
| 54758501 | PUBCHEM_CID |
| DB13164 | DRUGBANK_ID |
| D10859 | KEGG_DRUG |
| CHEMBL3989930 | ChEMBL_ID |
| 10093 | INN_ID |
| 9196 | IUPHAR_LIGAND_ID |
| C000617753 | MESH_SUPPLEMENTAL_RECORD_UI |
Pharmaceutical products:
None